HUMALOG KWIKPEN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for HUMALOG KWIKPEN (HUMALOG KWIKPEN).
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on skeletal muscle and adipose tissue, facilitating glucose uptake, and inhibiting hepatic glucose production.
| Metabolism | Presumably degraded by insulin protease or insulin-degrading enzyme; liver and kidney play a role in clearance. |
| Excretion | Renal: 60-80% of insulin lispro is metabolized primarily in the liver and kidneys, with metabolites and a small amount of intact drug excreted in urine. |
| Half-life | Terminal elimination half-life: approximately 26 minutes (range 0.6-1.2 hours in some studies) following subcutaneous administration, reflecting rapid clearance from the systemic circulation. |
| Protein binding | Weakly bound to plasma proteins, primarily albumin, with negligible binding (<10%). |
| Volume of Distribution | Vd: 0.2-0.4 L/kg (approximates extracellular volume, indicating limited tissue distribution). |
| Bioavailability | Subcutaneous: approximately 55-75% (variable by injection site and technique). Intravenous: 100%. |
| Onset of Action | Subcutaneous: 15-30 minutes (peak effect at 30-70 minutes). Intravenous: Immediate onset. |
| Duration of Action | Subcutaneous: 3-5 hours (dose-dependent; shorter with lower doses, may extend at higher doses). |
Subcutaneous injection: individualize dose; typical total daily dose 0.5-1 unit/kg; rapid-acting insulin given 0-15 minutes before or immediately after meals.
| Dosage form | SOLUTION |
| Renal impairment | eGFR <30 mL/min: consider dose reduction due to increased risk of hypoglycemia; monitor glucose closely. |
| Liver impairment | Child-Pugh class A-C: no specific recommendations; monitor glucose closely due to altered gluconeogenesis. |
| Pediatric use | Individualize based on weight: prepubertal children 0.5-0.7 units/kg/day; adolescents 0.7-1.0 units/kg/day; rapid-acting component covers prandial needs. |
| Geriatric use | Start with lower doses (e.g., 0.2-0.4 units/kg/day) to avoid hypoglycemia; titrate gradually; monitor renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for HUMALOG KWIKPEN (HUMALOG KWIKPEN).
| Breastfeeding | Insulin lispro is excreted in human milk in negligible amounts. The M/P ratio is not established but insulin is a large molecule with low oral bioavailability. It is considered compatible with breastfeeding, though caution is advised due to potential effects on neonatal glucose metabolism. Mothers may breastfeed while using Humalog KwikPen. |
| Teratogenic Risk | Insulin lispro does not cross the placenta in significant amounts. No increased risk of major malformations has been observed with its use during pregnancy. Poorly controlled maternal diabetes carries higher fetal risks including congenital anomalies (first trimester), macrosomia, neonatal hypoglycemia, and respiratory distress (second and third trimesters). |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypoglycemia","Hypersensitivity to insulin lispro or any excipients"]
| Precautions | ["Hypoglycemia is the most common adverse effect","Changes in insulin strength, manufacturer, type, or method of administration may affect glycemic control","Need for dose adjustment in renal or hepatic impairment","Risk of hypokalemia","Fluid retention and heart failure with concomitant use of thiazolidinediones"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose levels frequently. Assess HbA1c quarterly. Fetal surveillance includes ultrasound for growth and anatomy, nonstress testing, and biophysical profile as clinically indicated. Monitor for maternal hypoglycemia, especially during labor and delivery. |
| Fertility Effects | No adverse effects on fertility have been reported in animal studies. In humans, poorly controlled diabetes may impair fertility; improved glycemic control with insulin lispro may restore normal fertility. |